Inebilizumab
Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD19 |
| Clinical data | |
| Pronunciation | /ɪˌnɛbɪˈlɪzjʊmæb/ i-NE-bi-LIZ-yuu-mab |
| Trade names | Uplizna |
| Other names | MEDI-551, inebilizumab-cdon |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic agent |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6504H10080N1732O2044S44 |
| Molar mass | 146652.90 g·mol−1 |
The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain.
Inebilizumab was approved for medical use in the United States in June 2020, and in the European Union in April 2022. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.